MNPR · Monopar Therapeutics Inc.

Monopar Therapeutics announced first quarter 2026 financial results showing a net loss of $3.9 million, or $0.46 per share, compared to $2.6 million, or $0.38 per share, in the prior year quarter. The increased loss was primarily driven by a significant rise in R&D expenses to $3.5 million from $1.6 million, attributed to an $826 thousand increase in contractor and consulting costs, $800 thousand in personnel expenses including stock-based compensation, and $218 thousand in other R&D costs. G&A expenses also edged up to $1.7 million from $1.6 million, mainly from higher personnel costs. Offset partially by interest income doubling to $1.3 million due to higher balances from the September 2025 $91.9 million capital raise invested in U.S. Treasuries and commercial paper. Balance sheet remains strong with $137.5 million in cash, cash equivalents, and investments as of March 31, 2026, sufficient to fund operations through at least December 31, 2027, covering ALXN1840 regulatory submission and potential commercialization, MNPR-101 development, and internal R&D. On the business front, positive Phase 3 FoCus trial data for ALXN1840 in Wilson disease was presented at major conferences including AAN in April 2026, with upcoming posters at EAN and EASL in May/June 2026, highlighting superior neurologic benefits and liver stabilization versus standard of care. The company reaffirmed its NDA submission timeline to FDA in mid-2026, with new Chief Commercial Officer Susan Rodriguez, who joined in March, advancing commercial readiness activities.